Skip to main content
SpringerLink
Log in

The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience

  • Chapter
  • First Online:
Breast Cancer Research and Treatment

Part of the book series: Cancer Treatment and Research ((CTAR,volume 188))

  • 344 Accesses

Abstract

There is a growing global debate over barriers affecting the timely access to innovative anticancer therapies. Access to medicines is often traced back to the issue of costs: however, more commonly, the distance between valuable innovative treatments and the actual treatment of patients is far beyond the mere problem of financial barriers. A comprehensive approach to understand, assess to medicines should be pursued, to dissect the determinants and formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group “ONCOLLEGE”.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71:209–249

    Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30

    Article  PubMed  Google Scholar 

  3. Cherny NI, Sullivan R, Torode J, Saar M, Eniu A (2017) ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe. Ann Oncol: Offic J Euro Soc Med Oncol 28:2633–2647

    Article  CAS  Google Scholar 

  4. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:92–98

    Article  CAS  PubMed  Google Scholar 

  5. Pondé NF, Zardavas D, Piccart M (2019) Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol 16:27–44

    Article  PubMed  Google Scholar 

  6. Amin DN, Sergina N, Lim L, Goga A, Moasser MM (2012) HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J 447:417–425

    Article  CAS  PubMed  Google Scholar 

  7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  8. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Ittu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B (2016) Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice. Springerplus 5:395–495

    Article  PubMed  PubMed Central  Google Scholar 

  10. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724–734

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131

    Article  Google Scholar 

  12. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D'Amico R (2012)Trastuzumab containing regimens for early breast cancer. In: The Cochrane database of systematic reviews, pp CD006243-CD43

    Google Scholar 

  13. Shulman LN, Wagner CM, Barr R, Lopes G, Longo G, Robertson J, Forte G, Torode J, Magrini N (2016) Proposing essential medicines to treat cancer: methodologies processes, and outcomes. J Clin Oncol 34:69–75

    Article  CAS  PubMed  Google Scholar 

  14. Robertson J, Barr R, Shulman LN, Forte GB, Magrini N (2016) Essential medicines for cancer: WHO recommendations and national priorities. Bull World Health Organ 94:735–742

    Article  PubMed  PubMed Central  Google Scholar 

  15. Lee SM, Jung JH, Suh D, Jung YS, Yoo SL, Kim DW, Kim JA, Suh DC (2019) Budget impact of switching to biosimilar trastuzumab (CT-P6) for the treatment of breast cancer and gastric cancer in 28 European countries. BioDrugs 33:423–436

    Article  PubMed  Google Scholar 

  16. Giralt AN, Ronse M, Ravinetto R (2020) A survey of nongovernmental organizations on their use of WHO’s prequalification programme. Bull World Health Organ 98:413–419

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ (2000) Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18:3651–3664

    Article  CAS  PubMed  Google Scholar 

  18. Fornier M, Risio M, Van Poznak C, Seidman A (2002) HER2 testing and correlation with efficacy of trastuzumab therapy. Oncology (Williston Park) 16:1340–1348, 51–52; discussion 52, 55–58

    Google Scholar 

  19. Han HS, Kim JS, Park JH, Jeon YK, Lee KW, Oh DY, Kim JH, Park SY, Im SA, Kim TY, Park IA, Bang YJ (2009) Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy. J Korean Med Sci 24:910–917

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Singer CF, Köstler WJ, Hudelist G (2008) Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies. Biochim Biophys Acta 1786:105–113

    CAS  PubMed  Google Scholar 

  21. Vocaturo A, Novelli F, Benevolo M, Piperno G, Marandino F, Cianciulli AM, Merola R, Donnorso RP, Sperduti I, Buglioni S, Mottolese M (2006) Chromogenic in situ hybridization to detect HER-2/neu gene amplification in histological and ThinPrep-processed breast cancer fine-needle aspirates: a sensitive and practical method in the trastuzumab era. Oncologist 11:878–886

    Article  CAS  PubMed  Google Scholar 

  22. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726

    Article  CAS  PubMed  Google Scholar 

  23. Lidgren M, Wilking N, Jönsson B, Rehnberg C (2008) Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol 47:1018–1028

    Article  CAS  PubMed  Google Scholar 

  24. Wilson ML, Fleming KA, Kuti MA, Looi LM, Lago N, Ru K (2018)Access to pathology and laboratory medicine services: a crucial gap. Lancet 391:1927–1938

    Google Scholar 

  25. Chavarri-Guerra Y, St Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE (2017) Real world patterns of care in HER2-overexpressing breast cancer: results of a survey of TEACH clinical trial investigators in 2011. Breast 31:197–201

    Article  CAS  PubMed  Google Scholar 

  26. Trapani D, Lengyel CG, Habeeb BS, Altuna SC, Petrillo A, El Bairi K, Hussain S, Mazher SA, Elfaham EM, Curigliano G, Khan SZ (2021) The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: the ONCOLLEGE-001 survey. J Cancer Policy 28:100285

    Article  CAS  PubMed  Google Scholar 

  27. Altuna SC, Lengyel C, Trapani D, Elfaham EM, Hussain S, Petrillo A, El Bairi K, Mazher SA, Habeeb BS, Khan SZ (2019) 42P_PR—Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study. Ann Oncol 30:iii14

    Google Scholar 

  28. Desai A, Gyawali B (2020) Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions. EClinicalMedicine 20:100269

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zafar SY, Peppercorn JM, Schrag D, Taylor DH, Goetzinger AM, Zhong X, Abernethy AP (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience. Oncologist 18:381–390

    Article  PubMed  PubMed Central  Google Scholar 

  30. Gershon N, Berchenko Y, Hall PS, Goldstein DA (2019) Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff Resour Allocation: C/E 17:5–5

    Article  Google Scholar 

  31. Genuino AJ, Chaikledkaew U, Guerrero AM, Reungwetwattana T, Thakkinstian A (2019) Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines. BMC Health Serv Res 19:874

    Article  PubMed  PubMed Central  Google Scholar 

  32. de Lima Lopes G Jr (2011) Societal costs and benefits of treatment with trastuzumab in patients with early HER2neu-overexpressing breast cancer in Singapore. BMC Cancer 11:178

    Google Scholar 

  33. Pichon-Riviere A, Garay OU, Augustovski F, Vallejos C, Huayanay L, Bueno Mdel P, Rodriguez A, de Andrade CJ, Buendía JA, Drummond M (2015) Implications of global pricing policies on access to innovative drugs: the case of trastuzumab in seven Latin American countries. Int J Technol Assess Health Care 31:2–11

    Article  PubMed  Google Scholar 

  34. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ (2015) A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 151:27–40

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Erfani P, Bhangdia K, Stauber C, Mugunga JC, Pace LE, Fadelu T (2021) Economic evaluations of breast cancer care in low- and middle-income countries: a scoping review. Oncologist 26:e1406–e1417

    Article  PubMed  PubMed Central  Google Scholar 

  36. Chi M (2019) The hidden cost of cancer: helping clients cope with financial toxicity. Clin Soc Work J 47:249–257

    Article  Google Scholar 

  37. Mehnert-Theuerkauf A, Esser P (2022) Survivorship care plans for cancer patients: the importance of risk stratification, self-management and health literacy in the age of digital care. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 65:412–419

    Article  PubMed  PubMed Central  Google Scholar 

  38. Carrera PM, Kantarjian HM, Blinder VS (2018) The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin 68:153–165

    Article  PubMed  PubMed Central  Google Scholar 

  39. Bellanger M, Zeinomar N, Tehranifar P, Terry MB (2018) Are global breast cancer incidence and mortality patterns related to country-specific economic development and prevention strategies? J Glob Oncol 4:1–16

    PubMed  Google Scholar 

  40. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R (2009) Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 373:240–249

    Article  CAS  PubMed  Google Scholar 

  41. Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D’Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr (2020) Patient-reported outcomes from KATHERINE: a phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer 126:3132–3139

    Article  CAS  PubMed  Google Scholar 

  42. Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J (2020) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 21:519–530

    Article  CAS  PubMed  Google Scholar 

  43. Sivaram S, Perkins S, He M, Ginsburg E, Dominguez G, Vedham V, Katz F, Parascandola M, Bogler O, Gopal S (2021) Building capacity for global cancer research: existing opportunities and future directions. J Cancer Educ 36:5–24

    Article  PubMed  PubMed Central  Google Scholar 

  44. Ntekim A, Ibraheem A, Adeniyi-Sofoluwe A, Adepoju T, Oluwasanu M, Aniagwu T, Awolude O, Balogun W, Kotila O, Adejumo P, Babalola CP, Arinola G, Ojengbede O, Olopade CO, Olopade OI (2020) Implementing oncology clinical trials in Nigeria: a model for capacity building. BMC Health Serv Res 20:713

    Article  PubMed  PubMed Central  Google Scholar 

  45. The WHO’s ESSENCE project. https://www.who.int/tdr/partnerships/essence/meetings/en/

  46. FDA Expanded Access. https://www.fda.gov/news-events/public-health-focus/expanded-access

  47. Papazisis KT, Habeshaw T, Miles DW (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. Int J Clin Pract 58:581–586

    Google Scholar 

  48. Trastuzumab FDA Approval Letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/trasgen092598l.pdf

  49. Cherny N, Sullivan R, Torode J, Saar M, Eniu A (2016) ESMO European consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol 27:1423–1443

    Article  CAS  PubMed  Google Scholar 

  50. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, Van Damme W (2013) Access to medicines from a health system perspective. Health Policy Plan 28:692–704

    Article  PubMed  Google Scholar 

  51. de Souza JA, Wong YN (2013) Financial distress in cancer patients. J Med Person 11

    Google Scholar 

  52. Gatta G, Trama A, Capocaccia R (2013) Variations in cancer survival and patterns of care across Europe: roles of wealth and health-care organization. J Natl Cancer Inst Monogr 2013:79–87

    Article  PubMed  Google Scholar 

  53. Munro AJ (2014) Comparative cancer survival in European countries. Br Med Bull 110:5–22

    Article  PubMed  Google Scholar 

  54. Wheeler SB, Spencer JC, Pinheiro LC, Carey LA, Olshan AF, Reeder-Hayes KE (2018) Financial impact of breast cancer in black versus white women. J Clin Oncol 36:1695–1701

    Article  PubMed  PubMed Central  Google Scholar 

  55. Quick JD, Hogerzeil HV, Velasquez G, Rago L (2002) Twenty-five years of essential medicines. Bull World Health Organ 80:913–914

    PubMed  PubMed Central  Google Scholar 

  56. Ensor T, Cooper S (2004) Overcoming barriers to health service access: influencing the demand side. Health Policy Plan 19:69–79

    Article  PubMed  Google Scholar 

  57. Peters DH, Garg A, Bloom G, Walker DG, Brieger WR, Rahman MH (2008) Poverty and access to health care in developing countries. Ann N Y Acad Sci 1136:161–171

    Article  PubMed  Google Scholar 

  58. Burki T (2010) The real cost of counterfeit medicines. Lancet Infect Dis 10:585–586

    Article  PubMed  Google Scholar 

  59. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ (2005) The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med 2:e100

    Article  PubMed  PubMed Central  Google Scholar 

  60. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ (2011) The primacy of public health considerations in defining poor quality medicines. PLoS Med 8:e1001139

    Article  PubMed  PubMed Central  Google Scholar 

  61. Tran G, Yousuf Zafar S (2018) Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 6:166–266

    Article  PubMed  PubMed Central  Google Scholar 

  62. Dieleman JL, Baral R, Birger M, Bui AL, Bulchis A, Chapin A, Hamavid H, Horst C, Johnson EK, Joseph J, Lavado R, Lomsadze L, Reynolds A, Squires E, Campbell M, DeCenso B, Dicker D, Flaxman AD, Gabert R, Highfill T, Naghavi M, Nightingale N, Templin T, Tobias MI, Vos T, Murray CJ (2016) US spending on personal health care and public health, 1996–2013. JAMA 316:2627–2646

    Article  PubMed  PubMed Central  Google Scholar 

  63. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML (2011) Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 103:117–128

    Article  PubMed  PubMed Central  Google Scholar 

  64. CML-Experts (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121:4439–4442

    Google Scholar 

  65. Wickham RJ (2016) Value and Financial Toxicity of New Cancer Drugs. J Adv Pract Oncol 7:371–374

    PubMed  PubMed Central  Google Scholar 

  66. Bestvina CM, Zullig LL, Yousuf Zafar S (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 10:2189–2199

    Article  CAS  PubMed  Google Scholar 

  67. Bernard DS, Farr SL, Fang Z (2011) National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001 to 2008. J Clin Oncol 29:2821–2826

    Article  PubMed  PubMed Central  Google Scholar 

  68. Narang AK, Nicholas LH (2017) Out-of-pocket spending and financial burden among medicare beneficiaries with cancer. JAMA Oncol 3:757–765

    Article  PubMed  PubMed Central  Google Scholar 

  69. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb P (2016) Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 34:980–986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Yezefski T, Schwemm A, Lentz M, Hone K, Shankaran V (2018) Patient assistance programs: a valuable, yet imperfect, way to ease the financial toxicity of cancer care. Semin Hematol 55:185–188

    Article  PubMed  Google Scholar 

  71. Zullig LL, Wolf S, Vlastelica L, Shankaran V, Zafar SY (2017) The role of patient financial assistance programs in reducing costs for cancer patients. J Manag Care Spec Pharm 23:407–411

    PubMed  Google Scholar 

  72. Zafar SY, Peppercorn J, Asabere A, Bastian A (2017) Transparency of industry-sponsored oncology patient financial assistance programs using a patient-centered approach. J Oncol Pract 13(3):e240–e248. https://doi.org/10.1200/JOP.2016.017509

  73. Pisu M, Richman J, Allison JJ, Dale Williams O, Kiefe CI (2009) Pharmaceuticals companies’ medication assistance programs: potentially useful but too burdensome to use? South Med J 102:139–144

    Article  PubMed  Google Scholar 

  74. Access to Healthcare Roche’s global commitment. https://www.roche.com/dam/jcr:ad690046-6fa5-4ef0-8506-c29319247ad5/en/drug_donation_policy.pdf

  75. Donkor A, Atuwo-Ampoh VD, Yakanu F, Torgbenu E, Ameyaw EK, Kitson-Mills D, Vanderpuye V, Kyei KA, Anim-Sampong S, Khader O, Khader J (2022) Financial toxicity of cancer care in low- and middle-income countries: a systematic review and meta-analysis. Support Care Cancer

    Google Scholar 

  76. Pramesh CS, Badwe RA, Bhoo-Pathy N, Booth CM, Chinnaswamy G, Dare AJ, de Andrade VP, Hunter DJ, Gopal S, Gospodarowicz M, Gunasekera S, Ilbawi A, Kapambwe S, Kingham P, Kutluk T, Lamichhane N, Mutebi M, Orem J, Parham G, Ranganathan P, Sengar M, Sullivan R, Swaminathan S, Tannock IF, Tomar V, Vanderpuye V, Varghese C, Weiderpass E (2022) Priorities for cancer research in low- and middle-income countries: a global perspective. Nat Med 28:649–657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Radich JP, Briercheck E, Chiu DT, Menon MP, Sala Torra O, Yeung CCS, Warren EH (2022) Precision medicine in low- and middle-income countries. Annu Rev Pathol 17:387–402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Trapani D, Curigliano G (2020) How can biosimilars change the trajectory of breast cancer therapy? Expert Rev Anticancer Ther 20:325–328

    Article  CAS  PubMed  Google Scholar 

  79. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G (2022) Global challenges and policy solutions in breast cancer control. Cancer Treat Rev 104:102339

    Article  PubMed  Google Scholar 

  80. Kassem L, Shohdy KS, Abdel-Azeez AM, Attia H (2019) Is the fixed-dose intravenous trastuzumab policy warranted in limited-resource settings? J Glob Oncol 5:1–3

    PubMed  Google Scholar 

  81. Waller CF, Möbius J, Fuentes-Alburo A (2021) Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. Br J Cancer 124:1346–1352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Dent S, Ammendolea C, Christofides A, Edwards S, Incekol D, Pourmirza B, Kfoury S, Poirier B (2019) A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Curr Oncol 26:e70–e80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Manevy F, Filkauskas G, Levy P, Fredriksson J, Sussell J (2021) Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States. J Clin Oncol 39:544–644

    Article  Google Scholar 

  84. Fixed-Dose Pertuzumab/Trastuzumab Combo Approved in Europe for HER2+ Breast Cancer (2022). https://www.onclive.com/view/fixed-dose-pertuzumab-trastuzumab-combo-approved-in-europe-for-her2-breast-cancer

  85. Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga JY, Jung KH, Schem C, Hogea A, Badovinac Crnjevic T, Heeson S, Shivhare M, Kirschbrown WP, Restuccia E, Jackisch C (2021) Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol 22:85–97

    Article  CAS  PubMed  Google Scholar 

  86. Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A, Kaufman PA, Tabernero J, García-Estévez L, Schmid P, Arribas J (2020) Enhancing global access to cancer medicines. CA Cancer J Clin 70:105–124

    Article  PubMed  Google Scholar 

  87. International Agency for Research on Cancer, Global Cancer Observatory (2020). http://gco.iarc.fr/

  88. Barrios CH, Reinert T, Werutsky G (2019) Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab. Ecancermedicalscience 13:898

    Article  PubMed  PubMed Central  Google Scholar 

  89. Burstein HJ, Curigliano G, Thürlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP, Gnant M (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International consensus guidelines for treatment of early breast cancer 2021. Ann Oncol: Offic J Euro Soc Med Oncol 32:1216–1235

    Article  CAS  Google Scholar 

  90. Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol: Offic J Euro Soc Med Oncol 31:1623–1649

    Article  CAS  Google Scholar 

  91. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol: Offic J Euro Soc Med Oncol 32:1475–1495

    Article  CAS  Google Scholar 

  92. Shulman LN, Mpunga T, Tapela N, Wagner CM, Fadelu T, Binagwaho A (2014) Bringing cancer care to the poor: experiences from Rwanda. Nat Rev Cancer 14:815–821

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This research received no external funding.

Author information

Authors and Affiliations

  1. Head and Neck Surgery, National Institute of Oncology Hungary, 1122, Budapest, Hungary

    Csongor György Lengyel

  2. Department of Medical Oncology, Shaqlawa Teaching Hospital, Shaqlawa, Erbil, 44005, Iraq

    Baker Shalal Habeeb

  3. Medical Oncology Department, Oncomédica C.A, Caracas, 1010, Venezuela

    Sara Cecilia Altuna

  4. Department of Oncology and Hematology, University of Milan, 20122, Milan, Italy

    Dario Trapani

  5. Department of Clinical Oncology, Bannu Institute of Nuclear Medicine Oncology and Radiotherapy (BINOR), Bannu, Khyber Pakhtunkhwa, Pakistan

    Shah Zeb Khan

  6. Leicester Royal Infirmary, University Hospitals of Leicester, Leicester, LE1 5WW, UK

    Sadaqat Hussain

Authors
  1. Csongor György Lengyel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baker Shalal Habeeb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Cecilia Altuna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dario Trapani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shah Zeb Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sadaqat Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Csongor György Lengyel .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco

    Ouissam Al Jarroudi

  2. Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco

    Khalid El Bairi

  3. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy

    Giuseppe Curigliano

Ethics declarations

C.G.L. reports employment by Bristol Myers Squibb. Other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lengyel, C.G., Habeeb, B.S., Altuna, S.C., Trapani, D., Khan, S.Z., Hussain, S. (2023). The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience. In: Al Jarroudi, O., El Bairi, K., Curigliano, G. (eds) Breast Cancer Research and Treatment. Cancer Treatment and Research, vol 188. Springer, Cham. https://doi.org/10.1007/978-3-031-33602-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-33602-7_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-33601-0

  • Online ISBN: 978-3-031-33602-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation